<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137978">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047981</url>
  </required_header>
  <id_info>
    <org_study_id>OPP1032340-A</org_study_id>
    <nct_id>NCT02047981</nct_id>
  </id_info>
  <brief_title>Mortality Reduction After Oral Azithromycin: Mortality Study</brief_title>
  <acronym>MORDOR</acronym>
  <official_title>Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Mortality Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>Niger: Institutional Review Board</authority>
    <authority>Malawi: College of Medicine Research and Ethics Committee</authority>
    <authority>Tanzania: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our long-term goal is to more precisely define the role of mass azithromycin treatments as
      an intervention for reducing childhood mortality. We propose a single multi-site
      (multi-country), cluster-randomized trial comparing communities randomized to oral
      azithromycin with those randomized to placebo. We hypothesize that mass azithromycin
      treatments will reduce childhood mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will assess childhood mortality over two years, comparing communities where children aged
      1-60 months receive biannual oral azithromycin (&quot;Azithromycin&quot; arm), to communities where
      the children receive biannual oral placebo (&quot;Control&quot; arm).

      This is a cluster-randomized trial; at each site, communities within a contiguous area of
      300,000 to 600,000 individuals will be randomized to azithromycin or placebo using simple
      random sampling.

      Specific Aims

      Specific Aim 1: To test the hypothesis that mass distributions of oral azithromycin targeted
      to 1-60 month old children reduces childhood mortality, in a cluster-randomized trial

      Specific Aim 2: To assess the cost-effectiveness of mass azithromycin in reducing childhood
      mortality
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause Mortality Rate in children aged 1-60 months</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is a single multi-site trial, with each country as a secondary analysis. Also, an interim analysis of efficacy and futility will be conducted according to a pre-specified plan in the SAP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Mortality Rate in children aged 1-60 months, as assessed from verbal autopsy</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of mass azithromycin administration, per averted childhood death</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause and cause-specific health clinic visits in 1-60 month-old children</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">227000</enrollment>
  <condition>Childhood Mortality</condition>
  <arm_group>
    <arm_group_label>Biannual mass oral azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biannual mass oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years</description>
    <arm_group_label>Biannual mass oral azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years</description>
    <arm_group_label>Biannual mass oral placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Communities

          -  The community location in target district.

          -  The community leader consents to participation in the trial

          -  The community's estimated population is between 200-2,000 people.

          -  The community is not in an urban area.

        Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as
        assessed via biannual census.

        Exclusion Criteria:

        Individuals

        - Refusal of village chief (for village inclusion), or refusal of parent or guardian (for
        individual inclusion)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom M Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole E Stoller, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom M Lietman, MD</last_name>
    <phone>415-502-2662</phone>
    <email>tom.lietman@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole E Stoller, MPH</last_name>
    <phone>415-476-2460</phone>
    <email>Nicole.Stoller@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Proctor Foundation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Lietman, MD</last_name>
      <phone>415-502-2662</phone>
      <email>tom.lietman@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicole E Stoller, MPH</last_name>
      <phone>415-476-2460</phone>
      <email>Nicole.Stoller@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tom M Lietman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheila West, PhD</last_name>
      <phone>410-955-2606</phone>
      <email>shwest@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>College of Medicine at the University of Malawi, Blantyre</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khumbo Kalua</last_name>
      <phone>+265 999958176</phone>
      <email>kkalua@medcol.mw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Carter Center, Niger</name>
      <address>
        <city>Niamey</city>
        <country>Niger</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Salissou Kane</last_name>
      <phone>+227 20 73 28 57</phone>
      <email>mohamedsalissoukane@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kongwa Trachoma Project</name>
      <address>
        <city>Kongwa</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harran Mkocha</last_name>
      <phone>+255 26232 31 33</phone>
      <email>hmkocha@yahoo.com, ktp.2012@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London School of Hygiene &amp; Tropical Medicine</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Bailey, MRCP, PhD</last_name>
      <phone>020 7927 2914</phone>
      <email>Robin.Bailey@lshtm.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Malawi</country>
    <country>Niger</country>
    <country>Tanzania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 24, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Childhood mortality</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Mass treatment</keyword>
  <keyword>Infection</keyword>
  <keyword>Verbal Autopsy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
